Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Pro Medicus Limited ( (AU:PME) ) is now available.
Pro Medicus Limited has announced an update on its ongoing on-market buy-back program, with a recent acquisition of 3,924 ordinary fully paid securities. This buy-back strategy is part of the company’s efforts to manage its capital structure and potentially enhance shareholder value, reflecting a strategic move to optimize financial performance and market positioning.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$283.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging software solutions and services to healthcare professionals and institutions. The company focuses on delivering innovative medical imaging solutions that enhance diagnostic capabilities and improve patient care.
Average Trading Volume: 181,564
Technical Sentiment Signal: Buy
Current Market Cap: A$26.4B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.